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Received 6 October 2020; Revised 5 March 2021; Accepted 10 March 2021; Published 22 March 2021
Academic Editor: Tatsuharu Ohno
Copyright © 2021 Hanna L. M. Rajala et al. +is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Gemtuzumab-ozogamicin (GO) is a humanized anti-CD33 antibody, which is conjugated to a cytotoxic calicheamicin. It is used
to treat acute myeloid leukemia (AML) in combination with chemotherapy. We describe here two GO-treated acute myeloid
leukemia (AML) cases: both patients suffered from a toxic syndrome, which manifested as impaired hemoglobin-haptoglobin
scavenging and accumulation of hemolysis-related products. Our observations and earlier reports indicated that the reaction was
caused by GO-targeted destruction of CD33+CD163+ monocytes/macrophages, which are responsible for the clearance of
hemoglobin-haptoglobin complexes. +e rise of plasma lactate dehydrogenase was an early sign of the reaction, and both patients
had high levels of free plasma hemoglobin, but plasma haptoglobin and bilirubin levels were paradoxically normal. Symptoms
included septic fever and abnormalities in cardiac tests and in the case of the first patient, severe neurological symptoms which
required intensive care unit admittance. +erapeutic plasma exchanges supported the patients until the recovery of normal
hematopoiesis. +e symptoms may be easily confounded with infectious complications-related organ damage. Regarding the
increasing use of gemtuzumab-ozogamicin and other emerging CD33-targeted cell therapies, we want to highlight this mostly
unknown and probably underdiagnosed toxicity.
1. Introduction
Gemtuzumab-ozogamicin (GO) is a humanized anti-CD33
monoclonal antibody, which is linked to a very potent
cytotoxic agent and N-acetyl gamma calicheamicin. CD33
is expressed on the surface of most acute myeloid leukemia
(AML) blasts and on immature myeloid cells. [1] Adverse
events related to GO, such as cytopenias and liver toxicity,
led to its withdrawal from the market in 2010 due to failure
to demonstrate survival benefit because of increased tox-
icity-related mortality. [2] In 2017, GO regained its ap-
proval from the FDA and EMA, as studies on lower-dose
fractionated GO showed a better safety profile and bene-
ficial results overall, especially in AML patients with fa-
vorable cytogenetics [3–6].
In this report, we present two patients who suffered
from life-threatening GO-related impaired hemoglobin-
haptoglobin scavenging, which manifested as an atypical
intravascular hemolytic reaction. Earlier anecdotal reports
have suggested that GO-targeted destruction of
CD33 +CD163 + monocytes/macrophages leads to abro-
gated clearance of hemolysis-related products [7, 8]. Re-
garding the increasing use of GO and other emerging
CD33-targeted cell therapies, we want to highlight this
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unknown and poorly defined on-target/off-tumor toxicity
and share our experience of successful salvage with ther-
apeutic plasma exchanges (TPEs). Both patients consented
to the publication of the clinical data.
2. Case Presentation
Patient 1: A 21-year-old otherwise healthy female was
diagnosed with core-binding factor (CBF)-AML (t (8; 12)
(q21.3; q22)), corresponding RUNX1/RUNX1T1 tran-
script. After the first-line therapies (Table 1), minimal
residual disease (MRD) positivity of 0.02% was still de-
tected in the bone marrow (BM).+e patient then moved to
Finland. At the first visit to our center, a florid BM-relapse
was detected only 14 weeks after the start of the last
consolidation cycle. We initiated a course of 7 + 3 com-
bined with fractionated GO (Table 1). Along with sto-
matitis and cytarabine-related cutaneous reaction, from
day 13 onwards, the patient suffered from high fever,
malaise, Clostridium difficile colitis, and oral HSV infec-
tion. Moreover, Enterococcus faecium septicemia persisted
from day 21, though no deep foci of infection or endo-
carditis were detected. Human herpes virus 6 nucleic acid
test (HHV6-NAT) was positive on day 25 (Figure 1). As a
first sign of a toxic reaction, plasma lactate dehydrogenase
(P-LD) started to rise from day 11. +e reaction escalated
quickly from day 19, when blood samples became mac-
roscopically hemolytic. Free plasma hemoglobin (P-Hb)
rose markedly, but P-haptoglobin (P-Haptog) and P-Bili-
rubin (P-Bil) were paradoxically normal, unlike in typical
intravascular hemolysis (Figure 1, Table 2). Kidney and
liver tests remained normal, but plasma troponin I level
was elevated and the patient was hypertensive.
To lower the amount of toxic P-Hb and other potentially
harmful substances related to the hemolysis-like reaction
and to prevent further organ damage, therapeutic plasma
exchanges (TPEs) were performed on days 23–25, 36–38,
43–45, and 50–52. In each TPE, one volume of plasma
(about 5% of the patient’s weight) was exchanged and
replaced with 4–5% albumin and Octaplas-LG® plasma viadialysis catheter. We used citrate and the low-molecular
weight heparin, enoxaparin, as anticoagulants.
Despite wide-spectrum antibiotics and repeated TPEs,
septic fever did not respond to therapy. On day 35, the
patient was admitted to the intensive care unit (ICU) for four
days after a seizure. MRI scan showed cerebral micro-
hemorrhages. Cerebrospinal fluid (CSF) HHV6-NAT was
positive.
High levels of P-Hb and P-LD persisted until the first
signs of recovering hematopoiesis on day 45 (Figure 1,
Table 2). However, fever continued and new viral pneu-
monia-like changes were seen in the CT scan with subacute
cardiac tamponade requiring percutaneous pericardial
drainage. Immunological pericarditis and pneumonitis were
suspected and prednisolone 1mg/kg was started on day 63
with a clinical response. +e patient could finally be dis-
charged on day 81.
During follow-up, cardiac function has recovered and
pulmonary function improved partially. +e patient
remained in MRD-negative complete remission (CR) and
underwent allogeneic stem cell transplantation.
Patient 2: a 24-year-old female was diagnosed with CBF-
AML (inv16, corresponding CBFB-MYH11 fusion gene).
Pulmonary tuberculosis had been cured with nine months of
four-drug therapy one and a half years ago, but otherwise her
medical history was unremarkable. We initiated a course of
7 + 3 combined with a single dose of GO (Table 1). Wide-
spread cytarabine-related cutaneous reaction and mucositis
and high fever were observed from day 4 onwards. Blood
cultures and virus samples remained negative. Because of
suspected hyperinflammation (P-ferritin >16500 μg/L,
P-IL2R 5509 kU/L), we administered corticosteroid from
day 16: fever responded but P-LD was rapidly increasing.
P-Hb rose (410mg/L at highest), and the color of patient’s
plasma slightly darkened while P-Haptog and P-Bil stayed
normal. Hypertension and bradycardia were observed. We
did not see any other sign of target-organ damage caused by
the toxic reaction. We conducted preemptive TPEs daily on
days 20–22. No more TPEs were needed, as P-LD and P-Hb
declined after day 22 together with recovering hematopoi-
esis. CR with low MRD-positivity (CBFB-MYH11 0.02%)
was detected in the BM on day 29.
3. Discussion
We describe here a rare but life-threatening GO-related
on-target/off-tumor toxicity, from which the patients were
salvaged with TPEs until hematopoietic recovery. Based on
earlier publications, we suspected a hemolysis-like reac-
tion and accumulation of hemolysis-related products
caused by impaired hemoglobin-haptoglobin scavenging
[7, 8]. Previous reports describe patients who experienced
septic high fever and overall malaise, hypertension, neu-
rological symptoms, and abdominal pain. None survived,
either due to the persistent reaction or progressive disease
(Table 1).
In intravascular hemolysis, plasma haptoglobin is de-
pleted as it binds excess free hemoglobin to prevent its
toxicity and infiltration by the kidneys. CD33+ mature
tissue macrophages internalize the complexes via the
CD163 scavenger receptor [9]. Maniecki et al. speculated
that anti-CD33-mediated destruction of CD33 +CD163+
macrophages and subsequently impaired CD163-mediated
hemoglobin-haptoglobin scavenging leads to the para-
doxical accumulation of both plasma hemoglobin and
haptoglobin [7]. Our two patients did not have eminent
intravascular hemolysis, as they did not require red blood
cell transfusions at the beginning of the reaction.+e origin
of excess P-Hb is not known, but we suspect that it might be
partly related to anti-CD33-mediated destruction of red
pulp macrophages in the spleen: these cells are responsible
for maintaining hemoglobin-haptoglobin scavenging, and
their destruction might release free hemoglobin into
plasma. [10].
TPE is used to remove antibodies and immune com-
plexes from circulation [11]. It is the standard of care in
thrombotic thrombocytopenic purpura, in which it removes
ADAMTS13-blocking antibodies [12]. However, TPE is not
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g/dL (11.7–15.5) 11.9 12.1 NAA 7.4 7.5 9.3 9.9
B-WBC
x109/L (3.4–8.2) 3.9 0.1 0.1 0.8 0.4 5.7 6.0
B-PLTs
x109/L (150–360) 83 44 122 14 18 67 29
B-neutrophils
x109/L (1.5–6.7) 0.39 <0.05 <0.05 0.43 0.14 4.73 4.31
P-CRP
mg/L (<4) <4 28 411 216 266 57 33
P-Hb
mg/L (<50) 2167 376 186 87 77
P-LD
U/L (115–235) 201 513 1566 660 353 181 175
P-Haptog
g/L (0.29–2.0) 4.53 1.46 0.61
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Figure 1:+e clinical course of patient 1 (index case). Free plasma hemoglobin (P-Hb) and plasma lactate dehydrogenase (P-LD) are shown
on the left y-axis, and white blood cell count (WBC) on the right y-axis. We used metronidazole and fidaxomicin to treat colitis caused by
Clostridium difficile and valaciclovir for oral herpes simplex virus (HSV) infection. On day 21, blood culture (BC) was positive as the patient
had Enterococcus faecium septicemia which continued the following weeks despite repeated removals and replacements of catheters and use
of in vitro-effective antibiotics (tigecycline, linezolid, gentamicin, and daptomycin, which were selected because the patient was allergic to
vancomycin).+e patient tested positive for human herpes virus 6 nucleic acid test (HHV6-NAT) on day 25 and foscarnet was administered
from day 31. +erapeutic plasma exchanges started on day 23 with transient responses to P-Hb and P-LD levels. +e first signs of
granulopoiesis were seen in bone marrow (BM) aspirate on day 46, and we were able to withhold TPEs after day 52, as the reaction subsided
along with recovering hematopoiesis. Cumulative number of blood products transfused is shown below: there was no sign of hemolysis-
related increased red blood cell (RBC) consumption, as we transfused the first RBC unit on day 25.
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usually effective in autoimmune hemolytic anemia [13]. In
our patients, we used TPE to prevent toxicity related to free
plasma hemoglobin, heme, and other potentially toxic
molecules related to an inflammatory condition.
+e incidence of impaired hemoglobin-haptoglobin
scavenging related to GO is probably higher than reported,
and the clinical presentationmay vary from asymptomatic to
life-threatening. Infectious complications and related organ
damage during AML therapy may confound or delay the
detection of the reaction. +e currently recommended lower
dose of GO seems to be better tolerated, but the reaction is
probably dose-independent. Other CD33-targeting thera-
pies, such as CD33-directed chimeric antigen receptor
(CAR) T cells, are under investigation [14]. Similar toxicity
seems possible during CD33 CAR T cell therapy, and one
might speculate that the reaction could even be prolonged
due to the persistence of CAR T cells and enhanced by
cytokine release syndrome.
+e trigger responsible for tilting the scales towards
P-Hb accumulation is not known. Patient 1 had severe
infectious problems and patient 2 suffered from widespread
cytarabine-related skin toxicity, which might have con-
tributed to the hyperinflammatory status. We did not detect
germline mutations linked to immune deficiencies or in-
creased susceptibility to toxicity (skin biopsies and gene
panel sequencing).
According to our experiences, P-LD seems to be an early
biomarker for this severe adverse event.We suggest that P-LD
is followed in GO-treated patients, and if it rises, especially
1–2 weeks after GO administration (outside the time frame
for tumor lysis), P-Hb should be analyzed as well. Our first
patient survived this toxicity with repeated TPEs, and a
similar reaction was suspected in the case of the second
patient. Based on our experience, the initiation of TPEs might
support patients through bone marrow hypoplasia, until the
recovery of normal hemoglobin-haptoglobin scavenging.
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